JP2013543492A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543492A5 JP2013543492A5 JP2013530810A JP2013530810A JP2013543492A5 JP 2013543492 A5 JP2013543492 A5 JP 2013543492A5 JP 2013530810 A JP2013530810 A JP 2013530810A JP 2013530810 A JP2013530810 A JP 2013530810A JP 2013543492 A5 JP2013543492 A5 JP 2013543492A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- buffer
- carbetocin
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 19
- 239000000872 buffer Substances 0.000 claims 4
- NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 claims 4
- 229960001118 carbetocin Drugs 0.000 claims 4
- 108700021293 carbetocin Proteins 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 230000003078 antioxidant effect Effects 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000034423 Delivery Diseases 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000003169 placental effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 230000009677 vaginal delivery Effects 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- 206010061974 Gastrointestinal obstruction Diseases 0.000 claims 1
- 206010021718 Induced labour Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 claims 1
- 208000036064 Surgical Blood Loss Diseases 0.000 claims 1
- 206010046763 Uterine atony Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000006651 lactation Effects 0.000 claims 1
- 208000004396 mastitis Diseases 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 150000003890 succinate salts Chemical group 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10251690.3 | 2010-09-30 | ||
| EP10251690 | 2010-09-30 | ||
| PCT/IB2011/002394 WO2012042371A2 (en) | 2010-09-30 | 2011-09-29 | Pharmaceutical composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016215212A Division JP6250770B2 (ja) | 2010-09-30 | 2016-11-02 | 医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013543492A JP2013543492A (ja) | 2013-12-05 |
| JP2013543492A5 true JP2013543492A5 (enExample) | 2014-07-31 |
| JP6038797B2 JP6038797B2 (ja) | 2016-12-07 |
Family
ID=43478408
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530810A Active JP6038797B2 (ja) | 2010-09-30 | 2011-09-29 | 医薬組成物 |
| JP2016215212A Expired - Fee Related JP6250770B2 (ja) | 2010-09-30 | 2016-11-02 | 医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016215212A Expired - Fee Related JP6250770B2 (ja) | 2010-09-30 | 2016-11-02 | 医薬組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9566311B2 (enExample) |
| EP (5) | EP3222272B1 (enExample) |
| JP (2) | JP6038797B2 (enExample) |
| KR (2) | KR101919119B1 (enExample) |
| CN (4) | CN104906032A (enExample) |
| AU (1) | AU2011309762B2 (enExample) |
| BR (2) | BR122021001123B1 (enExample) |
| CA (1) | CA2812510A1 (enExample) |
| CY (2) | CY1119245T1 (enExample) |
| DK (4) | DK4374878T3 (enExample) |
| ES (4) | ES2637988T3 (enExample) |
| FI (1) | FI4374878T3 (enExample) |
| HR (3) | HRP20171256T1 (enExample) |
| HU (4) | HUE034367T2 (enExample) |
| IL (3) | IL225238B (enExample) |
| JO (3) | JO3400B1 (enExample) |
| LT (3) | LT4374878T (enExample) |
| MX (3) | MX395271B (enExample) |
| NZ (1) | NZ609719A (enExample) |
| PL (4) | PL4374878T3 (enExample) |
| PT (4) | PT3222272T (enExample) |
| RS (3) | RS62873B1 (enExample) |
| RU (2) | RU2737264C2 (enExample) |
| SI (4) | SI4374878T1 (enExample) |
| SM (3) | SMT202500165T1 (enExample) |
| TW (6) | TWI750934B (enExample) |
| WO (1) | WO2012042371A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070224184A1 (en) * | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| US20150099703A1 (en) * | 2012-05-08 | 2015-04-09 | Dilafor Ab | Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent |
| RS65144B1 (sr) * | 2014-09-19 | 2024-02-29 | Ferring Bv | Postupak za lečenje prader-vilijevog sindroma |
| RU2719416C2 (ru) | 2014-10-01 | 2020-04-17 | Окситон Байосайенс Б.В. | Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество |
| CN106999436B (zh) | 2014-10-01 | 2021-07-02 | 奥克希托恩生物科学公司 | 含有分娩控制物质的口服崩解固体药物剂量单元 |
| PL3242676T3 (pl) | 2015-01-07 | 2024-07-15 | Tonix Pharma Limited | Preparaty oksytocyny zawierające magnez i sposoby ich stosowania |
| WO2016162819A1 (en) * | 2015-04-07 | 2016-10-13 | Lupin Limited | Stable aqueous pharmaceutical composition of anti-tnf alpha antibody |
| HRP20250215T1 (hr) | 2016-04-12 | 2025-06-20 | Tonix Pharma Limited | Formulacije oksitocina koje sadrže magnezij i postupci upotrebe |
| CN107773531B (zh) * | 2016-08-31 | 2021-05-04 | 成都倍特药业股份有限公司 | 一种马来酸麦角新碱注射液 |
| CN108236601B (zh) * | 2016-12-23 | 2020-04-17 | 深圳翰宇药业股份有限公司 | 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法 |
| AU2018312956B2 (en) * | 2017-08-11 | 2022-03-10 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
| GB201721846D0 (en) * | 2017-12-22 | 2018-02-07 | Arecor Ltd | Novel composition |
| EP3759121A1 (en) | 2018-03-01 | 2021-01-06 | Trigemina, Inc. | Labeled oxytocin and method of manufacture and use |
| CN108721598B (zh) * | 2018-07-03 | 2020-06-05 | 北京市新里程医药科技有限公司 | 一种缩宫素原料的制备方法及其药物组合物和制剂 |
| US20200093884A1 (en) * | 2018-09-20 | 2020-03-26 | Mark C. Manning | Stable intranasal formulations of carbetocin |
| EP3852724A4 (en) | 2018-09-20 | 2022-07-06 | Levo Therapeutics, Inc. | CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE |
| CN109745544B (zh) * | 2018-11-23 | 2024-11-08 | 南京新百药业有限公司 | 稳定的缩宫素药物组合物及其制备方法 |
| EP3897571A1 (en) * | 2018-12-21 | 2021-10-27 | Arecor Limited | Novel composition |
| WO2020137880A1 (ja) * | 2018-12-27 | 2020-07-02 | 国立大学法人北海道大学 | オキシトシン誘導体及びその使用 |
| KR20220011697A (ko) | 2019-05-22 | 2022-01-28 | 바이오비에 아이앤씨. | 테를리프레신 제형 |
| CN110308222A (zh) * | 2019-07-17 | 2019-10-08 | 武汉赛沃医药科技有限公司 | 一种卡贝缩宫素原料药有关物质检测方法 |
| CN110403904A (zh) * | 2019-07-26 | 2019-11-05 | 翔宇药业股份有限公司 | 卡贝缩宫素注射液及其应用 |
| CN110237230A (zh) * | 2019-07-31 | 2019-09-17 | 南京康舟医药科技有限公司 | 一种卡贝缩宫素药物组合物及其制备方法 |
| WO2021089554A1 (en) | 2019-11-04 | 2021-05-14 | Ferring B.V. | Intranasal administration of merotocin for improving lactation |
| CN111012739A (zh) * | 2019-12-04 | 2020-04-17 | 长春圣金诺生物制药有限公司 | 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液 |
| WO2022200568A1 (en) | 2021-03-26 | 2022-09-29 | Ot4B | Treatment of dysphagia |
| CN114191388B (zh) * | 2021-12-27 | 2023-06-09 | 苏州天马医药集团天吉生物制药有限公司 | 一种卡贝缩宫素制剂的制备方法 |
| CN114712483B (zh) * | 2022-05-12 | 2023-09-29 | 成都倍特药业股份有限公司 | 一种麦角新碱缩宫素复方注射液及其制备方法和用途 |
| US12214010B2 (en) | 2023-04-04 | 2025-02-04 | Tulex Pharmaceuticals Inc. | Desmopressin oral compositions |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
| CN1109558A (zh) * | 1994-11-07 | 1995-10-04 | 马文亮 | 装有压力表的双管气筒 |
| SE9604341D0 (sv) * | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| DE69736140T2 (de) | 1997-11-18 | 2007-04-19 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Pharmazeutische injizierbare Lösungen, die Paracetamol und Kombinationen aus Paracetamol mit anderen Aktivsubstanzen enthalten |
| US6333313B1 (en) | 1998-10-29 | 2001-12-25 | Board Of Regents, The University Of Texas System | Clinical use of oxytocin alone or in combination to treat bone disorders |
| US6894026B1 (en) * | 2000-01-11 | 2005-05-17 | Atossa Healthcare, Inc. | Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders |
| US20070032410A1 (en) * | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| JP2001233787A (ja) | 2000-02-04 | 2001-08-28 | Patents Exploitation Co Bv | 小・中サイズのペプチド含有薬学的組成物 |
| AT409081B (de) * | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| ATE477811T1 (de) | 2002-10-03 | 2010-09-15 | Neuropharmacology Services Llc | Oxytocin zur behandlung von autismus und asperger-syndrom |
| ES2321297T3 (es) | 2003-01-08 | 2009-06-04 | Novartis Vaccines And Diagnostics, Inc. | Composiciones acuosas estabilizadas que comprenden inhibidor de la via del factor tisular (ivft) o variante del inhibidor de la via del factor tisular. |
| WO2004078147A2 (en) | 2003-03-05 | 2004-09-16 | Pr Pharmaceuticals | Oxytocin controlled release formulations and methods of using same |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| EP2167040A1 (en) * | 2007-06-07 | 2010-03-31 | MDRNA, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| SI2162011T1 (sl) | 2007-07-02 | 2011-05-31 | Sime Darby Malaysia Berhad | Mešanica rastlinskih maščob in jedilni proizvodi, ki vsebujejo takšno mešanico maščob |
| ES2319054B1 (es) * | 2007-08-06 | 2010-02-12 | Gp Pharm S.A. | Composicion farmaceutica oral de desmopresina. |
| RU2496788C2 (ru) * | 2008-03-31 | 2013-10-27 | Ферринг Б.В. | Аналоги окситоцина |
| CN104013569A (zh) * | 2008-10-15 | 2014-09-03 | 精达制药公司 | 高浓缩药物颗粒、制剂、混悬剂及其应用 |
-
2011
- 2011-09-28 JO JOP/2011/0297A patent/JO3400B1/ar active
- 2011-09-29 AU AU2011309762A patent/AU2011309762B2/en active Active
- 2011-09-29 PT PT171693286T patent/PT3222272T/pt unknown
- 2011-09-29 TW TW109142907A patent/TWI750934B/zh active
- 2011-09-29 SI SI201132130T patent/SI4374878T1/sl unknown
- 2011-09-29 EP EP17169328.6A patent/EP3222272B1/en not_active Revoked
- 2011-09-29 RS RS20220052A patent/RS62873B1/sr unknown
- 2011-09-29 CN CN201510212609.XA patent/CN104906032A/zh active Pending
- 2011-09-29 BR BR122021001123-0A patent/BR122021001123B1/pt active IP Right Grant
- 2011-09-29 SI SI201131272T patent/SI2621468T1/sl unknown
- 2011-09-29 HR HRP20171256TT patent/HRP20171256T1/hr unknown
- 2011-09-29 LT LTEP24166417.6T patent/LT4374878T/lt unknown
- 2011-09-29 PL PL24166417.6T patent/PL4374878T3/pl unknown
- 2011-09-29 EP EP11776530.5A patent/EP2621468B1/en active Active
- 2011-09-29 KR KR1020137010256A patent/KR101919119B1/ko active Active
- 2011-09-29 TW TW104135836A patent/TWI661834B/zh active
- 2011-09-29 HU HUE11776530A patent/HUE034367T2/en unknown
- 2011-09-29 TW TW104135841A patent/TWI650134B/zh not_active IP Right Cessation
- 2011-09-29 ES ES11776530.5T patent/ES2637988T3/es active Active
- 2011-09-29 TW TW108110519A patent/TWI746951B/zh active
- 2011-09-29 DK DK24166417.6T patent/DK4374878T3/da active
- 2011-09-29 CN CN2011800464547A patent/CN103124554A/zh active Pending
- 2011-09-29 RS RS20250410A patent/RS66759B1/sr unknown
- 2011-09-29 TW TW106115818A patent/TWI680773B/zh active
- 2011-09-29 MX MX2016014747A patent/MX395271B/es unknown
- 2011-09-29 PL PL17169301T patent/PL3246018T3/pl unknown
- 2011-09-29 HU HUE17169301A patent/HUE057187T2/hu unknown
- 2011-09-29 US US13/824,132 patent/US9566311B2/en active Active
- 2011-09-29 RS RS20170827A patent/RS56220B1/sr unknown
- 2011-09-29 DK DK11776530.5T patent/DK2621468T3/en active
- 2011-09-29 CN CN201610930206.3A patent/CN107080832B/zh active Active
- 2011-09-29 TW TW100135257A patent/TWI532507B/zh active
- 2011-09-29 EP EP21192651.4A patent/EP3936117A1/en active Pending
- 2011-09-29 SM SM20250165T patent/SMT202500165T1/it unknown
- 2011-09-29 PT PT241664176T patent/PT4374878T/pt unknown
- 2011-09-29 HU HUE24166417A patent/HUE070972T2/hu unknown
- 2011-09-29 CA CA2812510A patent/CA2812510A1/en not_active Abandoned
- 2011-09-29 ES ES24166417T patent/ES3027637T3/es active Active
- 2011-09-29 MX MX2013003365A patent/MX352949B/es active IP Right Grant
- 2011-09-29 LT LTEP17169328.6T patent/LT3222272T/lt unknown
- 2011-09-29 CN CN201610930541.3A patent/CN107412728A/zh active Pending
- 2011-09-29 EP EP24166417.6A patent/EP4374878B1/en active Active
- 2011-09-29 HR HRP20211969TT patent/HRP20211969T1/hr unknown
- 2011-09-29 SI SI201132035T patent/SI3246018T1/sl unknown
- 2011-09-29 HR HRP20250382TT patent/HRP20250382T1/hr unknown
- 2011-09-29 DK DK17169328.6T patent/DK3222272T3/da active
- 2011-09-29 SI SI201132022T patent/SI3222272T1/sl unknown
- 2011-09-29 RU RU2016143751A patent/RU2737264C2/ru active
- 2011-09-29 PT PT117765305T patent/PT2621468T/pt unknown
- 2011-09-29 HU HUE17169328A patent/HUE056835T2/hu unknown
- 2011-09-29 KR KR1020187032634A patent/KR102102664B1/ko not_active Expired - Fee Related
- 2011-09-29 BR BR112013007362-4A patent/BR112013007362B1/pt active IP Right Grant
- 2011-09-29 RU RU2013112666/15A patent/RU2604690C2/ru active
- 2011-09-29 SM SM20220034T patent/SMT202200034T1/it unknown
- 2011-09-29 PT PT171693013T patent/PT3246018T/pt unknown
- 2011-09-29 NZ NZ609719A patent/NZ609719A/en unknown
- 2011-09-29 JP JP2013530810A patent/JP6038797B2/ja active Active
- 2011-09-29 LT LTEP11776530.5T patent/LT2621468T/lt unknown
- 2011-09-29 ES ES17169328T patent/ES2905561T3/es active Active
- 2011-09-29 SM SM20170420T patent/SMT201700420T1/it unknown
- 2011-09-29 EP EP17169301.3A patent/EP3246018B1/en active Active
- 2011-09-29 PL PL11776530T patent/PL2621468T3/pl unknown
- 2011-09-29 ES ES17169301T patent/ES2902418T3/es active Active
- 2011-09-29 PL PL17169328T patent/PL3222272T3/pl unknown
- 2011-09-29 WO PCT/IB2011/002394 patent/WO2012042371A2/en not_active Ceased
- 2011-09-29 DK DK17169301.3T patent/DK3246018T3/da active
- 2011-09-29 FI FIEP24166417.6T patent/FI4374878T3/fi active
- 2011-09-29 MX MX2016005537A patent/MX390779B/es unknown
-
2013
- 2013-03-14 IL IL225238A patent/IL225238B/en active IP Right Grant
-
2016
- 2016-04-27 IL IL245328A patent/IL245328B/en unknown
- 2016-04-27 IL IL245326A patent/IL245326B/en active IP Right Grant
- 2016-11-02 JP JP2016215212A patent/JP6250770B2/ja not_active Expired - Fee Related
- 2016-12-28 US US15/393,026 patent/US20170106043A1/en not_active Abandoned
- 2016-12-28 US US15/393,053 patent/US20170106044A1/en not_active Abandoned
-
2017
- 2017-08-23 CY CY20171100893T patent/CY1119245T1/el unknown
-
2018
- 2018-11-12 JO JOP/2018/0102A patent/JOP20180102B1/ar active
- 2018-11-12 JO JOP/2018/0103A patent/JOP20180103B1/ar active
-
2022
- 2022-02-01 CY CY20221100079T patent/CY1124924T1/el unknown
- 2022-07-12 US US17/863,319 patent/US20230124105A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Giger et al. | Biomedical applications of bisphosphonates | |
| US20170360982A1 (en) | Wound Healing Composition Involving Mineral Ions and Methylglyoxal, and Methods of Use | |
| FI4374878T3 (fi) | Karbetosiinia käsittävä farmaseuttinen koostumus | |
| HRP20140716T1 (hr) | Analozi oksitocina | |
| JP2011225596A5 (enExample) | ||
| JP2022050545A (ja) | 敗血症を処置するための方法および組成物 | |
| ES2664951T5 (es) | Composiciones que comprenden glicosaminoglicanos de baja viscosidad y uso de dicha composición en terapia de cistitis crónica | |
| JP2015512386A5 (enExample) | ||
| MX390101B (es) | Tratamiento medico que comprende administracion enteral de edaravona | |
| CN106163539A (zh) | 用于预防性传播感染的组合产品 | |
| TW201247612A (en) | Compositions for treating kidney disorders | |
| HRP20211696T1 (hr) | Postupak izrade fluoriranih olefina | |
| RU2015145451A (ru) | Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол | |
| RU2011134414A (ru) | Комбинация фульвовой кислоты для лечения различных состояний и болезней | |
| RU2017100906A (ru) | Ретосибан для лечения преждевременных родов | |
| CN104884070B (zh) | 盐和糖的混合物在制备用于治疗哺乳动物的阴道松弛综合征或阴道干燥疾病的药物中的用途 | |
| RU2418597C1 (ru) | Способ лечения хронического тонзиллита | |
| AR111313A1 (es) | Composición osmóticamente activa para diálisis | |
| RU2010136277A (ru) | Галеновая форма для трансмукозально-буккального введения триптанов | |
| CN109843266B (zh) | 稳定的布洛芬注射组合物 | |
| RU2466746C1 (ru) | Способ лечения больных бесплодием, обусловленным непроходимостью маточных труб и ановуляторным менструальным циклом | |
| RU2016145411A (ru) | Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости | |
| Baymishev et al. | Metrolek-O medicine use for the correction of dairy cows reproductive function | |
| RU2018143557A (ru) | Карбоновые кислоты, предназначенные для применения в раннем детстве | |
| CN106727275A (zh) | 一种治疗阴道炎的栓剂组合物 |